Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Fda removes sits at the center of this dementia and brain health question.
While recent headlines may suggest the FDA has removed cold medicines linked to dementia, the actual situation is more nuanced. The FDA has not formally removed diphenhydramine, doxylamine, or chlorpheniramine from the market, nor has it mandated dementia warnings on over-the-counter labels in the United States. However, mounting scientific evidence—particularly a landmark 2015 JAMA study showing adults 65 and older who took anticholinergic medications daily for three or more years had a 54% higher dementia risk—has prompted major health organizations to recommend that seniors avoid these common cold and sleep medicines entirely.
The disconnect between the research and FDA action matters deeply for anyone caring for an aging loved one, as understanding what these medications actually do in the aging brain can help prevent irreversible cognitive decline. The confusion likely stems from growing international concern about anticholinergic safety. While the FDA continues to classify diphenhydramine as “generally recognized as safe and effective” for occasional use, the European Medicines Agency has gone further, requiring warning labels about dementia risk on anticholinergic products. In the United States, the burden falls on patients and caregivers to understand the science and make informed choices—often with guidance from healthcare providers who may not be aware of the latest research linking these medications to long-term cognitive harm.
Table of Contents
- Which Cold Medicines Pose Dementia Risks?
- What Does the Research Actually Show About Long-Term Use?
- Why Hasn’t the FDA Taken Stronger Action?
- What Should Older Adults Use Instead?
- What About People Already Taking These Medications Long-Term?
- How Can Caregivers Help Protect Aging Loved Ones?
- The Future of Anticholinergic Safety in Aging
- Conclusion
Which Cold Medicines Pose Dementia Risks?
The three medications most consistently linked to dementia risk are all first-generation antihistamines found in popular over-the-counter products. Diphenhydramine, the active ingredient in Benadryl, Tylenol PM, and Advil PM, is perhaps the most widely used. Doxylamine, found in Unisom and many store-brand sleep aids, carries the same anticholinergic properties. Chlorpheniramine, common in older allergy and cold formulations, completes this trio.
What makes these medications problematic is not their immediate effect—they do reduce allergy symptoms, ease cold congestion, and help people fall asleep—but their long-term impact on acetylcholine, a neurotransmitter essential for memory and thinking. Anticholinergic drugs work by blocking acetylcholine receptors in the brain and body. For someone taking a single dose of Benadryl to manage seasonal allergies, this effect is temporary and generally harmless. But for seniors who reach for these medications regularly—say, taking a diphenhydramine-containing sleep aid nightly, or using antihistamine cough syrup several times weekly during cold season for several years—the cumulative impact appears to alter the brain’s chemistry in ways that increase dementia risk. A person taking these medications chronically may never realize they’re slowly accumulating neurological debt that may not be repaid until years later.
What Does the Research Actually Show About Long-Term Use?
The evidence linking anticholinergic medications to dementia comes from rigorous epidemiological studies, most notably the 2015 JAMA Internal Medicine study of over 3,000 older adults. researchers found that those taking anticholinergic medications cumulatively for three or more years had significantly higher dementia rates than those who used them only occasionally. The risk wasn’t small—it was more than 50% higher. What’s striking is that the risk appeared to depend on duration and cumulative exposure, not just frequency. This matters because it suggests that avoiding these medications, even though they’re available without a prescription, could be one of the most straightforward ways to reduce dementia risk in older age.
However, interpreting this research requires nuance. The studies are observational, meaning researchers tracked what people took and what happened to them, rather than randomly assigning people to take anticholinergics or not. This means some of the dementia risk could potentially be attributable to other factors—older adults with cognitive decline might be more likely to reach for sleep aids, for example. Nevertheless, multiple independent studies have replicated these findings, and the biological mechanism is plausible: anticholinergic drugs do reduce acetylcholine in the brain, and acetylcholine is critical for memory. Harvard Health and the National Geographic articles discussing this research note that even if the association is only partially causal, the risk-benefit calculation for seniors is clear: these medications should generally be avoided.
Why Hasn’t the FDA Taken Stronger Action?
The FDA’s approach to anticholinergic medications reflects a broader challenge in pharmaceutical regulation: balancing safety with access to effective treatments. Diphenhydramine and other first-generation antihistamines have decades of safety data for short-term use, which is why the FDA continues to deem them safe for that purpose. Additionally, these medications are inexpensive, widely available, and genuinely help many people manage immediate symptoms—allergy relief, cough suppression, and sleep initiation. Abruptly removing them would leave millions without easy alternatives, particularly older adults and those with limited incomes.
Another factor is that the FDA operates within a different regulatory framework than some international bodies. The European Medicines Agency has more authority to mandate warning labels and restrict aging populations’ access to certain drugs. In the United States, the FDA can request label changes, issue guidance documents, and fund research, but it typically moves cautiously with OTC products that have historical approval. The result is that American seniors often lack the explicit warnings available in Europe, even though the scientific evidence is similar. Consumers and healthcare providers must seek out this information themselves—information that many primary care doctors may not be familiar with, especially if they’re not regularly reading geriatric medical journals.
What Should Older Adults Use Instead?
For someone 65 or older who reaches for a Benadryl to manage seasonal allergies, several safer alternatives exist. Second-generation antihistamines like cetirizine (Zyrtec), loratadine (Claritin), and fexofenadine (Allegra) work by the same mechanism as first-generation drugs but don’t cross the blood-brain barrier as readily, meaning they have minimal anticholinergic activity in the brain. They’re equally available over-the-counter and cost roughly the same. The trade-off is that they may take an hour or two to kick in, whereas diphenhydramine works within 30 minutes, and some people report they’re slightly less sedating—which could be a benefit or drawback depending on whether sleepiness is desired.
For sleep troubles, the situation is more complex because second-generation antihistamines are less sedating overall. Melatonin supplements, while not a perfect sleep solution and not appropriate for everyone, carry no dementia risk and are tried by many older adults. Cognitive behavioral therapy for insomnia (CBT-I), available through therapists or online programs, addresses the underlying causes of sleep disruption and produces lasting results without medication. For cough during a cold, guaifenesin (the expectorant in Mucinex) or honey-based cough syrups offer alternatives. A healthcare provider can help tailor choices to individual situations, considering other medications, medical conditions, and personal preferences.
What About People Already Taking These Medications Long-Term?
If someone has been regularly taking diphenhydramine or doxylamine for months or years, the appropriate response is not panic. Stopping medications abruptly without medical guidance can sometimes cause problems. Instead, the conversation should happen with a healthcare provider—a family doctor, geriatrician, or pharmacist—who can review the person’s complete medication list, understand why they started taking anticholinergics, and work out a gradual transition plan if one is needed. Some older adults may have compelling reasons to continue short-term use of these drugs despite the risks, and that’s a personal decision between them and their doctor.
The important limitation here is that dementia develops over years and involves many contributing factors—genetics, cardiovascular health, cognitive engagement, sleep quality, and more. Taking an anticholinergic medication for a few weeks during a cold or occasional use for jet lag is unlikely to cause dementia. The risk appears concentrated in people using these medications regularly for years. This is why the research is so valuable: it provides a clear, actionable signal that long-term regular use should be avoided, while acknowledging that occasional, short-term use may carry minimal risk.
How Can Caregivers Help Protect Aging Loved Ones?
For adult children or other caregivers managing medications for an aging parent, taking inventory of their medicine cabinet is a practical first step. Look for brand names like Tylenol PM, Advil PM, and Unisom. Read the active ingredients on nighttime cold and cough formulations. If an older adult is taking these regularly, bring it up at their next doctor’s appointment, armed with the information from this article.
Some healthcare providers may not be aware of the dementia research or may not have considered it relevant to their patient’s care. Being an advocate—kindly and collaboratively, not confrontationally—can prompt a medication review that might prevent cognitive decline. It’s also worth noting that some anticholinergic medications are prescription drugs. Older adults taking medications like oxybutynin for overactive bladder, antihistamines prescribed for allergies, or tricyclic antidepressants for pain or mood should discuss their dementia risk specifically with their prescribing doctor. The risk-benefit analysis for a prescription medication where anticholinergic properties are a side effect, rather than the main purpose, may differ from OTC sleep aids.
The Future of Anticholinergic Safety in Aging
Public awareness of anticholinergic risks is gradually increasing, driven by published research and coverage in mainstream health publications. Some healthcare systems and geriatric practices are already flagging anticholinergic medications in electronic health records and prompting reviews when older patients are prescribed them. If this trend continues, the next five years may see shifts in prescribing patterns and over-the-counter product formulations—possibly with manufacturers developing new versions that don’t rely on anticholinergic ingredients, or with clearer labeling.
The ideal outcome would combine better FDA labeling, easier access to alternative medications, and more healthcare provider education about anticholinergic risks in aging brains. Until that happens, individuals and families must take responsibility for understanding which medications carry dementia risk and working with their healthcare providers to avoid them. The science is clear enough that waiting for stronger regulatory action should not stop anyone from making safer choices today.
Conclusion
The FDA has not removed diphenhydramine, doxylamine, or chlorpheniramine from the market, and these medications remain available without prescription in thousands of products across America. However, strong scientific evidence—particularly the 2015 JAMA study showing 54% higher dementia risk in older adults taking anticholinergics long-term—justifies treating these common cold and sleep aids as substances to be avoided by anyone 65 and older, especially for regular or long-term use. The disconnect between research and regulation means that caregivers and patients must take an active role in reviewing medications and seeking alternatives.
If you or a family member regularly relies on anticholinergic cold or sleep medicines, the next step is a conversation with a healthcare provider about safer options. Second-generation antihistamines, behavioral approaches to sleep problems, and other alternatives exist. Making that change now—before dementia symptoms emerge—is one of the few medication decisions that can potentially preserve cognitive health and independence in later life.
You Might Also Like
- FDA Issues Warning About Common Sleep Aid Linked to Dementia Risk
- University of Colorado Identifies Common Sleep Aid That Increases Dementia Risk by 79 Percent
- Vanderbilt Researchers Connect Acid Reflux Medications to 33 Percent Higher Dementia Risk
For more, see NIH MedlinePlus — dementia.
